Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β‐hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 41, Iss. 5, 2016-10 ,pp. : 552-558

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 601-609

John Wiley & Sons Inc

Access to resources Recommend Favorite

Midazolam microdosing

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 2, 2015-02 ,pp. : 278-285

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 401-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evidence of CYP3A Allosterism In Vivo: Analysis of Interaction Between Fluconazole and Midazolam

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 442-449

John Wiley & Sons Inc

Access to resources Recommend Favorite